Purpose: Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC).
Methods: In this open-label, phase III trial, patients with advanced HCC, previously untreated with systemic therapy, were randomly assigned in a 1:1 ratio to receive HAIC-FO or sorafenib. The primary end point was overall survival (OS) in the intention-to-treat population. An exploratory model for predicting the efficacy of HAIC-FO on the basis of genomic sequencing was developed.
Results: Between May 2017 and May 2020, 262 patients were randomly assigned. The median tumor size was 11.2 cm (interquartile range, 8.5-13.7 cm). Macrovascular invasion was present in 65.6%, and the percentage of patients with > 50% tumor volume involvement of the liver and/or Vp-4 portal vein tumor thrombosis was 49.2%. At data cutoff (October 31, 2020), median OS was 13.9 months for HAIC-FO and 8.2 for sorafenib (hazard ratio [HR] 0.408; 95% CI, 0.301 to 0.552; < .001). Tumor downstaging occurred in 16 (12.3% of 130) patients receiving HAIC-FO, including 15 receiving curative surgery or ablation, and finally achieving a median OS of 20.8 months, with a 1-year OS rate of 93.8%. In high-risk subpopulations, OS was significantly longer with HAIC-FO than with sorafenib (10.8 months 5.7 months; HR 0.343; 95% CI, 0.219 to 0.538; < .001). A newly developed 15-mutant-gene prediction model identified 83% of patients with response to HAIC-FO. HAIC-FO responders had longer OS than HAIC-FO nonresponders (19.3 months 10.6 months; HR 0.323; 95% CI, 0.186 to 0.560; = .002).
Conclusion: HAIC-FO achieved better survival outcomes than sorafenib in advanced HCC, even in association with a high intrahepatic disease burden.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.21.01963 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.
Front Immunol
October 2024
Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.
Article Synopsis
- The study aimed to determine the most effective first-line treatment for advanced hepatocellular carcinoma by systematically analyzing phase III trials over a significant period.
- A total of 17 studies involving over 10,000 patients were included, revealing that Hepatic artery infusion chemotherapy with oxaliplatin plus fluorouracil (HAIC-FO) provided notable overall survival benefits compared to other treatments like immune checkpoint inhibitors and traditional chemotherapy.
- HAIC-FO ranked highest in overall survival and objective response rate, while also performing well in progression-free survival, though it didn't outperform certain other combination therapies like lenvatinib with transcatheter arterial chemoembolization.
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
Crit Rev Oncol Hematol
December 2024
Department of interventional radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. Electronic address:
Article Synopsis
- The study focuses on finding safe and effective treatments for patients with advanced hepatocellular carcinoma (HCC), emphasizing the need for better options compared to existing first- and second-line therapies like sorafenib and T+A.* -
- A rigorous network meta-analysis will evaluate randomized controlled trials to compare treatment outcomes such as overall survival, progression-free survival, and response rates, helping to inform clinical decisions for HCC patients.* -
- Preliminary results indicate that HAIC-FO treatment outperforms the T+A regimen in terms of overall survival, progression-free survival, and objective response rates, suggesting more effective options for patients with advanced HCC.*
Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib.
Med Sci Monit
July 2024
Department of Oncology, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai, Shandong, China.
BACKGROUND The FOHAIC-1 trial showed hepatic arterial infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) improved survival, compared with sorafenib, in patients with advanced hepatocellular carcinoma (HCC). The aim of this study was to conduct a cost-effectiveness comparison between HAIC-FO and sorafenib from the perspective of the Chinese healthcare system. MATERIAL AND METHODS The economic evaluation was conducted between July 2023 and February 2024, spanning a 10-year investment horizon.
View Article and Find Full Text PDFComparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
Front Oncol
February 2024
Department of Pharmacy, An-Nan Hospital, China Medical University, Tainan, Taiwan.
Background: Portal vein tumor thrombus (PVTT) is a common complication and an obstacle to treatment, with a high recurrence rate and poor prognosis. There is still no global consensus or standard guidelines on the management of hepatocellular carcinoma (HCC) with PVTT. Increasing evidence suggests that more aggressive treatment modalities, including transarterial chemoembolization, radiotherapy, targeted therapy, and various combination therapies, may improve the prognosis and prolong the survival of advanced hepatocellular carcinoma (aHCC) patients with PVTT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!